SCHNEYER MARK C. 1899977 Data last updated 2024-05-14 07:02:16 -0500 US CDT
Latest Holdings
Notice: Data summarized from Form 3,4,5 filings, which do not include holdings/transactions of investment institution(s), if any, managed by the reporter.
Non-derivative Transactions CSV download
Tips: type "code_s" to show transactions with code "S".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-19 | 2023-05-17 | 2023-05-17 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | dsp | 15310.0 | 41.14 | 0.94 | 22.5 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code S | 21905.0 | 162.63 (ACAD) |
| 2023-05-19 | 2023-05-17 | 2023-05-17 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | acq | 29738.0 | 79.91 | 1.83 | 0.0 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code M | 37215.0
|
162.63 (ACAD) |
| 2023-06-12 | 2023-06-08 | 2023-06-08 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | dsp | 974.0 | 4.09 | 0.06 | 25.02 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code S | 22824.0 | 162.63 (ACAD) |
| 2023-06-12 | 2023-06-08 | 2023-06-08 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | acq | 1893.0 | 7.95 | 0.12 | 0.0 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code M | 23798.0 | 162.63 (ACAD) |
| 2023-08-23 | 2023-08-21 | 2023-08-21 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | dsp | 10000.0 | 38.94 | 0.61 | 29.0 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code S | 15682.0 | 163.73 (ACAD) |
| 2023-11-21 | 2023-11-17 | 2023-11-20 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | dsp | 5108.0 | 19.96 | 0.31 | 22.64 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code S | 20486.0 | 164.18 (ACAD) |
| 2023-11-21 | 2023-11-17 | 2023-11-17 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | acq | 9912.0 | 38.73 | 0.6 | 0.0 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code M | 25594.0
|
164.18 (ACAD) |
| 2024-02-27 | 2024-02-23 | 2024-02-23 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | acq | 1353.0 | 6.2 | 0.08 | 0.0 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code M | 21839.0 | 164.18 (ACAD) |
| 2024-02-27 | 2024-02-23 | 2024-02-26 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | dsp | 772.0 | 3.53 | 0.05 | 24.67 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code S | 21067.0 | 164.18 (ACAD) |
| 2024-03-27 | 2024-03-25 | 2024-03-25 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | acq | 10550.0 | 33.37 | 0.64 | 0.0 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code A | 31617.0 | 164.18 (ACAD) |
| 2024-03-27 | 2024-03-25 | 2024-03-27 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | dsp | 5434.0 | 17.19 | 0.33 | 17.9 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code S | 26183.0 | 164.18 (ACAD) |
| 2024-04-09 | 2024-04-05 | 2024-04-05 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | acq | 5275.0 | 16.77 | 0.32 | 0.0 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code M | 31458.0 | 164.18 (ACAD) |
| 2024-04-09 | 2024-04-05 | 2024-04-08 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | dsp | 2716.0 | 8.63 | 0.17 | 17.87 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code S | 28742.0 | 164.18 (ACAD) |
| 2024-05-03 | 2024-05-01 | 2024-05-01 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | acq | 6814.0 | 19.16 | 0.42 | 0.0 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code M | 35556.0 | 164.18 (ACAD) |
| 2024-05-03 | 2024-05-01 | 2024-05-02 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | dsp | 3503.0 | 9.85 | 0.21 | 16.94 | Direct | Common Stock | ACADIA PHARMACEUTICALS INC | code S | 32053.0 | 164.18 (ACAD) |
Derivative Transactions
Tips: type "code_m" to show transactions with code "M".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-19 | 2023-05-17 | 2023-05-17 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | dsp | 29738.0 | 54.55 | 1.83 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code M | 24782.0
|
162.63 (ACAD) |
| 2023-06-12 | 2023-06-08 | 2023-06-08 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | dsp | 1893.0 | 50.0 | 0.12 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code M | 1893.0 | 162.63 (ACAD) |
| 2023-11-21 | 2023-11-17 | 2023-11-17 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | dsp | 9912.0 | 33.33 | 0.6 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code M | 19826.0
|
164.18 (ACAD) |
| 2024-02-27 | 2024-02-23 | 2024-02-23 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | dsp | 1353.0 | 50.0 | 0.08 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code M | 1353.0 | 164.18 (ACAD) |
| 2024-03-27 | 2024-03-25 | 2024-03-25 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | acq | 24714.0 | 100.0 | 1.51 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code A | 24714.0 | 164.18 (ACAD) |
| 2024-03-27 | 2024-03-25 | 2024-03-25 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | acq | 80564.0 | 100.0 | 4.91 | 17.84 | Direct | Stock Options (Right To Buy) | ACADIA PHARMACEUTICALS INC | code A | 80564.0 | 164.18 (ACAD) |
| 2024-04-09 | 2024-04-05 | 2024-04-05 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | dsp | 5275.0 | 33.33 | 0.32 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code M | 10551.0 | 164.18 (ACAD) |
| 2024-05-03 | 2024-05-01 | 2024-05-01 | 4 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | dsp | 6814.0 | 25.0 | 0.42 | 0.0 | Direct | Restricted Stock Units | ACADIA PHARMACEUTICALS INC | code M | 20445.0 | 164.18 (ACAD) |
a Sum of same type of securities in the form
b Relative to reporter's shares owned before (disposition) or after (acquisition) operation
c Relative to issuer's shares outstanding (1/10000)
d Average price for securities of the same type. Check the original form for detailed prices of multiple transactions
e Documented shares outstanding closest to the transaction date
Note: Corporate may change mapped CIK when merge or spin-off happen. Please report error if the ticker you searched for does not have up-to-date insider trading information.
Show up to records per table for current tier. Access Guide)